Page 25 - JCBP-3-1

Journal of Clinical and
Basic Psychosomatics Somatic symptom disorder etiology

cAMP pathway: Dependence on glucocorticoid receptor doi: 10.1111/jne.13279
activation. J Neurosci. 2008;28(26):6642-6651.
92. Hasselmo ME, Wyble BP, Wallenstein GV. Encoding and
doi: 10.1523/jneurosci.1336-08.2008 retrieval of episodic memories: Role of cholinergic and
GABAergic modulation in the hippocampus. Hippocampus.
82. Mueller B, Figueroa A, Robinson-Papp J. Structural and
functional connections between the autonomic nervous 1996;6:693-708.
system, hypothalamic-pituitary-adrenal axis, and the doi: 10.1002/(SICI)1098-1063(1996)6:6<693:AID-HIPO
immune system: A context and time dependent stress 12>3.0.CO;2-W
response network. Neurol Sci. 2022;43(2):951-960.
93. Buhlman LM. Heterologous Expression of Alpha6*Nicotinic
doi: 10.1007/s10072-021-05810-1 Acetylcholine Receptors and the Natural Distribution of
Alpha6 Subunits. Dissertation. United States: University of
83. Nemeroff CB, Vale WW. The neurobiology of depression:
Inroads to treatment and new drug discovery. J Clin Arizona; 2007.
Psychiatry. 2005;66(Suppl 7):5-13. 94. Nabekura J, Murata O, Ishibashi H, Akaike N. Use-
dependent suppression of the nicotinic acetylcholine
84. Kamohara M, Matsuo A, Takasaki J, et al. Identification
of MrgX2 as a human G-protein-coupled receptor for receptor response by the proadrenomedullin N-terminal
proadrenomedullin N-terminal peptides. Biochem Biophys 20-amino acid peptide in rat locus coeruleus neurons.
Res Commun. 2005;330:1146-1152. J Neurochem. 1998;70:865-870.
doi: 10.1046/j.1471-4159.1998.70020865.x
doi: 10.1016/j.bbrc.2005.03.0888
95. Takano K, Yamashita N, Fujita T. Proadrenomedullin NH2-
85. Katoh F, Kitamura K, Niina H, et al. Proadrenomedullin +
N-terminal 20 peptide (PAMP), an endogenous terminal 20 peptide inhibits the voltage-gated Ca2 channel
anticholinergic peptide: Its exocytotic secretion and current through a pertussis toxin-sensitive G protein in
inhibition of catecholamine secretion in adrenal medulla. rat pheochromocytoma-derived PC 12 cells. J Clin Invest.
J Neurochem. 1995;64:459-461. 1996;98(1):14-17.
doi: 10.1172/JCI118758
doi: 10.1046/j.1471-4159.1995.64010459.x
96. Hardman JG, Limbird PB, Gilman AG, editors. Goodman
86. Masada K, Nagayama T, Hosokawa A, et al. Effects of
adrenomedullin and PAMP on adrenal catecholamine release and Gilman’s The Pharmacological Basis of Therapeutics.
th
in dogs. Am J Physiol Regul. 1999;276(4):R1118-R1124. 10 ed. New York: McGraw-Hill; 2001.
97. Iwasaki H, Hirata Y, Iwashina M, Sato K, Marumo F. Specific
doi: 10.1152/ajpregu.1999.276.4.R1118
binding sites for proadrenomedullin N-terminal 20 peptide
87. Travers S, Martinerie L, Xue QY, et al. Adrenomedullin: New (PAMP) in the rat. Endocrinology. 1996;137(7):3045-3050.
inhibitory regulator for cortisol synthesis and secretion.
J Endocrinol. 2021;251(1):97-109. doi: 10.1210/en.137.7.3045
98. Li GZ, Liang QC, Jin YH, et al. The effect of acetylcholine
doi: 10.1530/JOE-20-0564
on pain-related electric activities in the hippocampal CA3
88. Strohle A, Holsboer F. Stress responsive neurohormones of rats. J Neural Transm (Vienna). 2011;118(4):555-561.
in depression and anxiety. In: Kasper S, den Loer JA,
Sitsen JAM, editors. Handbook of Depression and Anxiety: doi: 10.1007/s00702-010-0545
A Biological Approach. United States: CRC Press; 2003. 99. Wenk GL. Neurodegenerative diseases and memory:
p. 207-228. A treatment approach. In: Kesner RP, Martinez JL Jr., editors.
nd
Neurobiology of Learning and Memory. 2 ed. Burlington,
89. Vinkers CH, Kuzminskaite E, Lamers F, Giltay EJ,
Penninx B. An integrated approach to understand biological MA: Academic Press; 2007. p. 621.
stress system dysregulation across depressive and anxiety 100. Meldrum BS. Glutamate as a neurotransmitter in the
disorders. J Affect Disord. 2021;283:139-146. brain: Review of physiology and pathology. J Nutr.
2000;130:1007S-1015S.
doi: 10.1016/j.jad.2021.01.051
doi: 10.1093/jn/130.4.1007S
90. Hasselmo ME, Wyble BP. Free recall and recognition in a
network model of the hippocampus: Simulating effects of 101. Rousseaux CG. A review of glutamate receptors II:
scopolamine on human memory function. Behav Brain Res. Pathophysiology and pathology. J Toxicol Pathol.
1997;89:1-34. 2008;21(3):133-173.
doi: 10.1016/S0166-4328(97)00048-x doi: 10.1293/tox.21.133
91. Sabban EL, Serova L, Nahvi RJ, Liu X. Potential benefits of 102. Jones PG, Dunlop J. Targeting the cholinergic system
intranasal neuropeptide Y include sustained extinction of as a therapeutic strategy for the treatment of pain.
fear memory. J Neuroendocrinol. 2023;35(11):e13279. Neuropharmacology. 2007;53:197-206.

Volume 3 Issue 1 (2025) 19 doi: 10.36922/jcbp.4254